（文章来源：央视新闻） 中国科学院空天信息创新研究院传感器技术全国重点实验室与哈尔滨医科大学附属第一医院神经外科联 合，近日成功完成"基于植入式微电极阵列的脑深部肿瘤边界精准定位"临床试验。这是全球范围内首次 脑机接口应用于脑深部肿瘤术中边界精准定位的临床试验，标志着我国自主研发的植入式临床脑机接口 技术实现重要突破。该技术为神经外科提供实时、高精度的"病灶导航"，有望在精准切除肿瘤的同时最 大程度保护健康脑组织，提升患者术后神经功能保留率和生活质量，具有重要的临床推广价值。 ...

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion in the pharmaceutical industry, particularly for Chinese companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring discussions and presentations from industry leaders [1]. Pharmaceutical Main Forum - The main forum will include several roundtable discussions, such as: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Blockbuster" [4]. - "Next-Generation Weight Loss Drug Development Hotspots and China's Pipeline Competitiveness" [5]. - "Which Disease and Technology Areas in Pharmaceuticals are Worth Expecting for Going Global?" [5]. - "The New Cycle of Chinese Innovative Drugs Under Global Competition: Breaking Through from R&D to Commercialization" [5]. - "Technological Upgrades: Exploring the Next Wave of Drug Development Platforms" [5]. - "The Future is Here: Dialogue on the New World of Brain-Machine Interfaces" [6]. - "Innovation Going Global" [6]. TMT Sub-Forum - The TMT sub-forum will cover topics such as: - "Outlook for the Two-Dimensional Animation Industry" [6]. - "How AI Disrupts the Game Industry Structure" [6]. - "The Future of AI Companion Toys" [6]. - "Innovations and Explorations in AI Immersive Video" [6]. - "ASIC and Internet Giants' Innovations" [7]. - "Demonstrations and Introductions of Brain-Machine Interface Products" [7]. Additional Discussions - The second day will feature discussions on AI's impact on finance and healthcare, including: - "AI Infrastructure Development" [9]. - "Current Status and Outlook of Direct Satellite Communication Technology in Domestic Mobile Phones" [9]. - "Future Development of AI Network Architecture" [9]. Industry Participation - The event will see participation from numerous leading companies in pharmaceuticals, medical devices, and technology sectors, including major players in drug development, medical services, and internet healthcare [13][15].

实际上，资本流入脑机接口领域的速度正在加快。IT桔子(北京岁月桔子科技有限公司)数据显示，截至 8月27日，年内脑机接口领域已发生投融资事件13起，金额共计9.23亿元；2024年全年，发生投融资事 件6起，金额共计2.01亿元。 具体来看，13起投融资事件中，有9起与医疗健康相关，1起与人工智能相关，其余3起涉及算法优化、 硬件开发等。受访专家普遍表示，脑机接口技术在医疗健康领域受到高度关注，被视为未来医疗健康发 展的重要方向之一，市场想象空间巨大。 国务院对外发布的《关于深入实施"人工智能+"行动的意见》提出，加快人工智能与元宇宙、低空飞 行、增材制造、脑机接口等技术融合和产品创新，探索智能产品新形态。 在政策与资本的共同驱动下，我国脑机接口领域正呈现出诸多特点：技术加速迭代，产业链上下游协同 发展；应用场景多点开花，较成熟的消费级产品已经出现；企业活跃度高、数量不断增长，市场规模持 续扩大。 今年以来，脑机接口多次出现在国家、地方的工作部署中。7月30日，工业和信息化部等七部门联合对 外发布了《关于推动脑机接口产业创新发展的实施意见》。3月份，国家医疗保障局编制印发了《神经 系统类医疗服务价格项目立项指 ...

Summary of Zhongke Information Conference Call Company Overview - **Company**: Zhongke Information - **Industry**: Technology and Medical Equipment Key Points and Arguments Order Growth and Financial Performance - Zhongke Information's new signed orders reached 677 million yuan, a year-on-year increase of 282.6%, setting a historical high and exceeding last year's total orders [3] - The company expects total orders for the year to reach 1 billion yuan or more, marking the highest order volume in its history [3] - As of June 30, the company had nearly 1 billion yuan in hand orders, with expectations for revenue recognition in the fourth quarter [3][5] Competitive Advantage in Sensitive Projects - The company holds a national first-class secret qualification, which includes sensitive integration, software, and operation qualifications, giving it a strong competitive edge in sensitive projects, particularly in Sichuan and Southwest China [5] - The significant achievements in the sensitive project sector are attributed to the unique qualifications that allow the company to secure numerous orders [5] New Business Directions and Technological Applications - Zhongke Information is actively expanding into new business areas such as brain-computer interfaces, AI anesthesia robots, and construction robots [2][6] - The AI anesthesia robot has completed 5 clinical trials and is expected to finish 200 human clinical trials by the end of next year, aiming for certification as a Class III innovative medical device [6] - The company collaborates with West China Hospital to develop a radiation therapy adaptive target area delineation system, enhancing the precision of radiation therapy [6] High-Speed Machine Vision Technology - The high-speed machine vision technology is widely applied in various industries, including digital meetings, tobacco, oil, currency printing, and medical fields [7] - This technology has monopolized six major currency printing factories and significantly reduced error rates, replacing manual inspections since 2012 [7] - The system can analyze over 5,400 points on a large banknote within 0.2 seconds, showcasing its high precision [7] Challenges and Solutions in Medical Imaging - West China Hospital faces challenges in completing target area delineation from CT or MRI results, which can take two to three weeks [8] - The new intelligent system developed in collaboration with Zhongke Information can reduce this time to about one week, significantly improving the efficiency of radiation therapy [8] Traditional Business Recovery - Traditional business areas such as digital meetings and tobacco have seen a recovery with an increase of nearly 30% [4][9] - The digital meeting system secured its first order for the Hong Kong Legislative Council election, marking a significant milestone for expansion into the Hong Kong and Macau markets [9] Future M&A and Asset Integration Plans - The company is actively seeking new acquisition targets within the Chinese Academy of Sciences system, focusing on automation, microelectronics, and nanotechnology [10] - Despite interest in these areas, progress has been limited due to the requirement for profitability in state-owned acquisitions [10] Additional Important Information - The company plans to leverage the Hong Kong and Macau regions as a springboard for global expansion of its digital meeting systems, which could have significant potential if the overseas market opens up [9] - The engineering loading robot developed to address labor shortages in road construction is being promoted in Sichuan and Tibet, with plans for further industrialization [4][9]

三博脑科 20250827 摘要 三博脑科上半年常性损益后净利润 7,201 万元，同比增长 10.74%；经 营活动现金流量 6,476 万元，同比下降 21%。基本和稀释每股收益 0.34 元，同比增长 6.25%。 新建院区床位利用率逐步提升，昆明三博新院区床位利用率已达 85%， 预计一年内达 100%；西安三博预计年底床位利用率达 40%，明年初达 60%。北京三博计划搬迁至新院区，新老院区同时运营，预计第一年度 床位利用率约 80%。 医保控费政策收紧，DRG/DIP 实施及非医保项目创新成应对策略。医保 政策收紧可能导致医院收入节奏推延半年至一年，医院利用盈利性医院 定价政策优势，开展脑健康管理等非医保项目以弥补收入损失。 三博脑科多层次布局脑科学领域，包括基础研究、临床应用和产业投资， 与清华大学等科研院所合作，推动科研成果转化，并设立四支脑科学基 金，投资人工智能与脑机接口领域。 脑机接口技术在医疗应用中前景广阔，三博脑科专注于生物医学与电子 信息技术相结合的脑机接口领域，与创新企业合作，验证提升其产品技 术，目标是将公司转型为医疗健康科技集团。 Q&A 请介绍一下三博脑科 2025 年上半 ...

Core Viewpoint - The development of China's medical equipment industry during the "14th Five-Year Plan" period has achieved significant progress, showcasing high-end medical equipment and innovative enterprises, which is transforming the healthcare landscape in China and globally [1][2]. Market Growth - The medical equipment industry in China has a compound annual growth rate of approximately 10.7% during the "14th Five-Year Plan," with the market size expected to reach 1.35 trillion yuan by 2024, making it the second-largest market globally [2]. - By the end of 2024, the number of medical device manufacturing companies in China is projected to exceed 33,000, representing a growth of 27.8% compared to the end of the "13th Five-Year Plan" [2]. Technological Advancements - Domestic medical equipment is increasingly moving towards high-end and intelligent solutions, with innovations such as zero-magnetic medical imaging devices and integrated radiation therapy technologies being introduced [3]. - Since the beginning of the "14th Five-Year Plan," 315 innovative medical devices have been approved, with 272 of them being domestic products, accounting for 86.3% [3]. - The domestic production of advanced medical technologies, such as carbon ion therapy systems and artificial hearts, has shifted from reliance on imports to achieving competitive and leading positions in certain products [3]. Clinical Applications - The integration of artificial intelligence and advanced imaging technologies has led to significant improvements in medical equipment, with over 1.045 million patent applications in the medical equipment field during the "14th Five-Year Plan" [4]. - Innovations like the full-body PET/CT scanner have drastically reduced scanning times and improved imaging capabilities, enhancing clinical applications [4]. - The introduction of remote-controlled surgical robots has improved precision and safety in surgeries, benefiting both patients and healthcare providers [6]. Policy Support - The Chinese government has implemented multiple policies to promote high-quality development in the medical equipment sector, focusing on research, industry, and application [7]. - Initiatives such as the "14th Five-Year Plan for Medical Equipment Industry Development" and the establishment of green channels for innovative medical devices are aimed at accelerating the adoption of new technologies [7]. Accessibility and Affordability - The advancements in domestic medical equipment have made healthcare services more accessible and affordable for the public, with significant price reductions for surgical robots enabling more hospitals to offer robotic surgeries [9]. - Technologies like AI-assisted diagnostics and remote surgical systems are breaking geographical barriers, allowing patients in rural areas to access quality medical services [9][10].

本次财报公布的各项数据指标表现一般。其中，毛利率27.43%，同比减41.28%，净利率0.97%，同比减 67.54%，销售费用、管理费用、财务费用总计1.41亿元，三费占营收比44.41%，同比增56.82%，每股净 资产1.75元，同比增1.84%，每股经营性现金流-0.02元，同比减262.56%，每股收益0.01元，同比增 81.54% 据证券之星公开数据整理，近期岩山科技（002195）发布2025年中报。截至本报告期末，公司营业总收 入3.17亿元，同比下降6.38%，归母净利润6710.75万元，同比上升81.51%。按单季度数据看，第二季度 营业总收入1.51亿元，同比下降7.72%，第二季度归母净利润3555.07万元，同比上升186.09%。本报告 期岩山科技三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达56.82%。 建议关注公司应收账款状况（应收账款/利润已达295.54%） | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.38亿 | 3.17亿 | -6.38 ...

Core Viewpoint - The company emphasizes a long-term development strategy amidst domestic market adjustments, focusing on quality management and promoting high-margin products while reducing low-margin sales [2][3]. Group 1: Domestic Market Strategy - The company is addressing the decline in the domestic market by maintaining strict operational quality and ensuring stable accounts receivable and reasonable inventory turnover [2]. - The company is committed to upgrading and promoting cloud products domestically to enhance profitability [2]. Group 2: High Gross Margin Drivers - The company's high gross margin is attributed to its focus on the global market, mastery of core algorithms, and self-production capabilities, which provide both technical and brand premium [3]. - Increasing overseas sales, which have a higher gross margin, is a key factor in the overall high gross margin, driven by customized demand and localized strategies [3]. Group 3: Collaboration and New Product Developments - The company is collaborating with Lingzu Technology to explore the integration of brain-computer interface (BCI) technology with robotics, aiming to build a multi-field collaborative innovation system [4]. - New products related to brain-computer technology showcased at a Thailand exhibition have garnered attention, although these products are still in the research and development phase [4]. - The company encourages investors to follow its official channels for updates on new product launches and acknowledges the uncertainties in new business development [4].

（编辑 王雪儿） 证券日报网讯 诚益通8月27日在互动平台回答投资者提问时表示，公司已确立"侵入式与非侵入式"双轨 并行的战略布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级 现有产品功能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用， 包括教育、养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口 生物反馈系统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司 在脑机接口领域的重要战略布局，两大中心将构建"基础研究-技术验证-成果转化"的完整创新链条。 ...

Market Overview - The market saw significant movements with several stocks hitting their daily limits, including Jingtu Qidian, Dongtianwei, and Huayuan Pharmaceutical, all achieving a 20% increase [1][2][3] - The overall market sentiment is mixed, with some stocks experiencing sharp declines, such as Wanfang Development and Chuanrun Shares, both hitting their lower limits [2][3] Key Stocks - **Yanshan Technology**: Reported a 10.07% increase, closing at 7.32, with a trading volume of 84.95 million and a turnover rate of 21.04% [3][5] - **Maigemi**: Achieved a 10% increase, closing at 86.03, with a trading volume of 28.17 million and a turnover rate of 7.26% [9][11] - **Tianrongxin**: Closed at 12.38, up 10.04%, with a trading volume of 45.50 million and a turnover rate of 33.56% [11][12] Trading Activity - The top net buying stocks on the day included Yanshan Technology, Maigemi, and Tianrongxin, with net purchases of 4.89 billion, 4.73 billion, and 2.47 billion respectively [3][4] - Conversely, the top net selling stocks included Huasheng Tiancai, Zhongdian Xindong, and Chuanrun Shares, with net sales of 3.22 billion, 2.41 billion, and 2.21 billion respectively [4][6] Institutional Activity - Institutional buying was notable in stocks like Bubu Gao and Yuyin Shares, with net purchases of 1.13 billion and 810.69 million respectively [14][15] - On the selling side, Wanfang Development and Zhongdian Xindong saw significant institutional net sales of 2.59 billion and 2.39 billion respectively [15][16] Sector Performance - The technology sector showed strong performance with multiple stocks achieving significant gains, particularly in AI and cloud computing [2][3] - Conversely, the agricultural sector faced challenges, with stocks like Wanfang Development and Chuanrun Shares experiencing sharp declines [2][3]